Clover Health Investments, Corp. CLOV
4.49
(0.02)
(0.44%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow CLOV
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.11 | 0.42 | 0.63 | 0.88 | |
P/FCF ratio |
37.01 | 16.85 | 0.00 | 0.00 | |
P/Operating CF |
109.05 | 8.52 | (17.65) | 129.64 | |
P/B ratio |
7.30 | 2.71 | 3.90 | 4.60 | |
Price to Tangible BV |
7.36 | 2.73 | 3.94 | 4.64 | |
EV/Sales |
1.01 | 0.33 | 0.57 | 0.77 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
32.56 | 12.57 | (16.24) | (16.20) | |
EV/FCF |
33.80 | 13.20 | (15.76) | (15.87) | |
Quick Ratio |
0.98 | 0.82 | 1.03 | 1.35 | |
Current Ratio |
1.50 | 1.33 | 1.47 | 1.71 | |
Net Debt/EBITDA |
(8.64) | (7.43) | 2.43 | 8.32 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.82 | 3.45 | 3.43 | 2.93 | |
Operating CF/Net income |
0.90 | 3.95 | 1.38 | (0.50) | |
Capex/Depreciation |
(5.01) | (11.54) | 7.37 | (69.20) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.74% | 17.58% | 25.24% | 19.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
1.22% | 1.64% | 5.11% | 5.26% | |
Graham Net Nets |
0.05 | 0.10 | 0.06 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.95%) | (6.82%) | (7.34%) | (3.68%) | |
Free Cash Flow Yield |
2.70% | 5.93% | (5.73%) | (5.51%) | |
Revenue per Share |
1.42 | 1.43 | 0.95 | 0.97 | |
Operating CF per Share |
0.05 | 0.21 | (0.13) | 0.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.05 | 0.21 | (0.13) | 0.02 | |
Cash per Share |
0.46 | 0.39 | 0.23 | 0.40 | |
Shareholders Equity per Share |
0.72 | 0.65 | 0.60 | 0.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.72 | 0.65 | 0.60 | 0.66 | |
Free Cash Flow |
24.51 | 107.04 | (68.75) | 11.41 | |
Working Capital |
162.12 | 111.44 | 99.03 | 137.47 | |
Capital Expenditures |
(0.68) | (0.85) | (0.60) | (0.69) | |
Net Current Asset Value |
141.38 | 89.72 | 75.55 | 112.19 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
3.77% | 3.65% | (10.11%) | (4.91%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
60.01 | 63.50 | 73.20 | 55.11 | |
Average Payables |
34.68 | 34.86 | 35.39 | 29.34 | |
Average Assets |
647.66 | 640.72 | 560.88 | 606.34 | |
Average Common Equity |
360.22 | 337.75 | 324.92 | 341.55 |
Columns are period end dates